Oropharyngeal Cancer (OPC) Market Research Report | OPC Market Size & Share

Oropharyngeal Cancer (OPC) Market Insights, Epidemiology and Market Forecast 2030

The oropharynx consists of the structures in the oral cavity, back of the throat, including the base of the tongue, palatine tonsils, posterior pharyngeal wall, and soft palate. These are the well-known areas can only be visualized using special endoscopes or mirrors. There are many types of cancer of the oropharynx.

Oropharyngeal cancer is a type of head and neck cancer. Patients with oropharyngeal cancer related to HPV tend to present earlier in life as compared to those with tobacco-associated oropharyngeal cancer. The primary tumor is often difficult to see, hidden within the folds of the throat (tongue-base and tonsil.)

DelveInsight's "Oropharyngeal Cancer - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Oropharyngeal Cancer, historical and forecasted epidemiology as well as the Oropharyngeal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

 

The Oropharyngeal Cancer market report provides current treatment practices, emerging drugs, Oropharyngeal Cancer market share of the individual therapies, current and forecasted Oropharyngeal Cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Oropharyngeal Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

·         The United States

·         EU5 (Germany, France, Italy, Spain, and the United Kingdom)

·         Japan

Study Period: 2017-2030

View full report: https://www.delveinsight.com/report-store/oropharyngeal-cancer-market

Oropharyngeal Cancer Disease Understanding and Treatment Algorithm

Cancer specific to the oropharynx is called oropharyngeal cancer-a type of head and neck cancer that accounts for around thousands of newly diagnosed cases in the US every year. The leading cause of head and neck cancers is smoking tobacco, and as smoking has become less common in recent years, so has the occurrence for most head and neck cancers. The exception to this is oropharyngeal cancer, which is drastically increasing, especially in the younger population. The earliest stage oral cavity or oropharyngeal cancers are called stage 0 (carcinoma in situ), and then range from stages I through IV. As a rule, the lower the number, the less the cancer has spread. A higher number, such as stage IV, means cancer has spread more.

Early sign of oropharyngeal cancer often include lump in the neck. Besides this, patients often present or complain with lump or mass in the neck and back of the throat, difficulty or pain with swallowing, muffled voice, and pain in ear and throat may also appear.

There are few prognostic factors for oropharyngeal carcinoma such as HPV status, smoking history (pack-year smoking history of ten or more years), and tumor stage and nodal status.

The assessment of the primary tumor is based on inspection and palpation, when possible, and by indirect mirror examination. Beside this, other procedures may be done to evaluate the primary tumor such as Positron emission tomography–computed tomography scan (PET-CT) scan, Magnetic resonance imaging, Endoscopy, Laryngoscopy, Biopsy and p16 testing to assess for HPV status.

The DelveInsight Oropharyngeal Cancer market report gives a thorough understanding of the Oropharyngeal Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Diagnosis 

This segment of the report covers the detailed diagnostic methods or tests for Oropharyngeal Cancer. 

Treatment 

It covers the details of conventional and current medical therapies available in the Oropharyngeal Cancer market for the treatment of the condition. It also provides Oropharyngeal Cancer treatment algorithms and guidelines in the United States, Europe, and Japan. 

Oropharyngeal Cancer Epidemiology  

The Oropharyngeal Cancer epidemiology division provide insights about historical and current Oropharyngeal Cancer patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Key Findings

 

  •          As per the Surveillance, Epidemiology, and End Results (SEER), approximately 1.2% of men and women will be diagnosed with oral cavity and pharynx cancer at some point during their lifetime (based on 2015–2017 data).
  •          According to the Stanford Medicine (US), Oropharyngeal Cancer cases typically are not diagnosed until the tumor metastasizes to the neck.
  •          As per the CDC (Centers for Disease Control and Prevention), approximately 70% of cancers of the oropharynx may be linked to HPV.

Request for sample pages: https://www.delveinsight.com/sample-request/oropharyngeal-cancer-market

Oropharyngeal Cancer Drug Chapters

The dynamics of the Oropharyngeal Cancer market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in development of drugs for Oropharyngeal Cancer. Key players, such as Precigen, and others are involved in developing drugs for Oropharyngeal Cancer.

Emerging therapies includes Validive by Monopar Therapeutics, ISA101b plus Cemiplimab by ISA Pharmaceuticals/ Regeneron Pharmaceuticals

Drug chapter segment of the Oropharyngeal Cancer report encloses the detailed analysis of Oropharyngeal Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Oropharyngeal Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Oropharyngeal Cancer Market Outlook

At present, there are several treatment choices for oropharyngeal cancer: surgery, radiation therapy, chemotherapy and targeted therapy. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemo-radiation. Even after the surgery, cancer cell can be seen, therefore, few patients may be given chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

The use of surgery in HPV-positive oropharyngeal cancer and the application of minimally invasive techniques to avoid or reduce required doses of adjuvant treatment have become important areas of study. Trans-oral laser surgery (TLS) was first popularized by Steiner in Germany. There has been increasing experience with TLS, but its use for oropharyngeal tumors has been limited to a few high-volume centers in the US and European units in the UK, France, and Germany

The Oropharyngeal Cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Oropharyngeal Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 

According to DelveInsight, Oropharyngeal Cancer market in 7MM is expected to change in the study period 2017-2030.

Scope of the Report

·         The report covers the descriptive overview of Oropharyngeal Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

·         Comprehensive insight has been provided into the Oropharyngeal Cancer epidemiology and treatment in the 7MM

·         Additionally, an all-inclusive account of both the current and emerging therapies for Oropharyngeal Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

·         A detailed review of Oropharyngeal Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM

·         The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Oropharyngeal Cancer market

Download full report: https://www.delveinsight.com/report-store/oropharyngeal-cancer-market

Request for sample pages: https://www.delveinsight.com/sample-request/oropharyngeal-cancer-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 


Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more